Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Vilaseca A, Bilodeau PA, Gakis G, Savransky A, Mahler Ferreira Oliveira J, Nguyen L, Hooshmand SI, Satyanarayan S, Moseley CE, Haley L, Roy-Hewitson C, Marrodan M, Casallas A, Manin A, Chen H, Hoshina Y, Grzezulkowska A, Carnero Contentti E, Galleguillos L, Upchurch M, Jackson-Tarlton CS, Chu-Yueh Guo J, Fabian M, Virupakshaiah A, Arrambide G, Caparó-Zamalloa C, Paterno R, Waubant E, Ordoñez Boschetti L, Correale J, Villa AM, Banwell B, Marignier R, Pittock SJ, Greenberg B, Bennett JL, Cho T, Clardy S, Solomon AJ, Kister I, Zamvil SS, Gelfand JM, Repovic P, Obeidat AZ, Blackburn K, Tenembaum S, Chen JJ, Sotirchos ES, Levy M, Flanagan EP; and The Americas MOGAD Treatment Group; Murillo F, Syc-Mazurzek SB, Cacciaguerra L, Jiang M, da Silva Rezende NB, Wingerchuk DM, Horsman SE.
Vilaseca A, et al. Among authors: chen h.
JAMA Neurol. 2026 Jul 13. doi: 10.1001/jamaneurol.2026.2220. Online ahead of print.
JAMA Neurol. 2026.
PMID: 42440328